What the trial was testing
The trial enrolled 165 patients with vasculitis. The study was sponsored by Poitiers University Hospital and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
Ultrasound correctly identified 54% of giant cell arteritis cases without needing a biopsy.
Annals of internal medicine · 2024 · NCT02703922
These findings — that ultrasound correctly found giant cell arteritis without biopsy — were published in the Annals of internal medicine and represent the headline result of the study.
Researchers tracked outcomes across 165 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with vasculitis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Ultrasound is already widely available and used for many conditions. This study suggests it can help diagnose giant cell arteritis faster, potentially avoiding biopsies. If you have symptoms like temple pain or vision changes, ask your doctor whether ultrasound might be appropriate for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open vasculitis trials
Vascular Lab Resource (VLR) Biorepository
This is a study of biomarkers obtained from prospectively collected subject samples and their correlation with cardiovascular and metabolic diseases. The purpose of this initiative is to develop an enduring tool to allow for collaborative research between clinicians at Cleveland Clinic Main Campus and basic scientists at the Lerner Research Institute. This collaboration will allow resources to be available to clinical and basic researchers alike. This tool will enable research of vascular disease in the Vascular Lab and will leverage this valuable asset to the fullest extent to allow for interdepartmental collaboration.
Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab to induce clinical and serological remission in patients with relapsing PR3-ANCA granulomatosis with polyangiitis.